Key Stability Testing Milestones Achieved for MRX1

Ananda Developments PLC

03 December 2024

 

3^rd December 2024

ANANDA DEVELOPMENTS PLC 

("Ananda" or the "Company") 

Key Stability Testing Milestones Achieved for MRX1

Ananda Developments plc (AQSE: ANA), a Company focused on the development of cannabidiol (CBD) based therapies for the treatment of a range of complex inflammatory pain conditions, is pleased to announce that its MRX1 CBD drug candidate has successfully passed through a number of critical drug stability timepoints ahead of its use in two Phase II and one Phase I clinical studies.

The term 'drug stability' refers to the extent to which a drug retains, within specified time limits throughout its period of storage and use, acceptably comparable properties and characteristics to that which it possessed at the time of manufacture.

Highlights:

·    Critical time points for stability achieved, confirming MRX1 will remain stable under standard conditions for the duration of the trials

·    MRX1 now moves towards the final set-up preparatory works ahead of its use in two Phase II clinical trials for Chemotherapy Induced Peripheral Neuropathy and Endometriosis, and a Phase I Pharmacokinetic study

·    For more information & to view an additional video by Jeremy Sturgess-Smith, Finance Director of Ananda Developments Plc, and the chance to have your questions directly answered by the management team, please head to our interactive investor hub via: https://investors.anandadevelopments.com/link/7PlXJP

The stability data confirms that MRX1 CBD drug candidate maintains its physical, chemical and microbiological properties within the required parameters, following the requirements of Good Manufacturing Practice standards. These developments represent significant progress as Ananda prepares to advance MRX1 into clinical trials.

Ananda's CEO, Melissa Sturgess commented: "Stability data ensures MRX1 will maintain its intended quality, safety, and efficacy throughout the clinical trial. It is not just a regulatory requirement but also critical to the scientific integrity of our studies, ensuring reliable results and protecting participant safety." 

-Ends-

To stay up to date with the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·   Investor Hub: investors.anandadevelopments.com

·   Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·   LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·   Twitter: https://twitter.com/AnandaPlc

·   Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-  

The Directors of the Company accept responsibility for the contents of this announcement.  

ANANDA DEVELOPMENTS PLC	[phone]
	[e-mail]
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP	[phone]
Corporate Finance
Richard Morrison
Caroline Rowe
Corporate Broking
Abigail Wayne
Rob Rees
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay	[phone] [e-mail]

About Ananda Developments  

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com

Market Abuse Regulation (MAR) Disclosure  

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

https://investors.anandadevelopments.com/link/7PlXJP

 

END